Lunit Presents 7 Studies Based on 'Lunit Scope' at AACR

Medical artificial intelligence (AI) company Lunit announced on the 6th that it will participate in the '2024 American Association for Cancer Research (AACR 2024)' held in San Diego, California, USA, from the 5th to the 10th of next month (local time), presenting seven research results demonstrating the role of AI technology in cancer treatment using its AI biomarker platform, Lunit SCOPE.

[Photo by Lunit]

AACR is considered one of the world's top three cancer conferences alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Lunit has participated for six consecutive years since 2019, continuously showcasing the latest research results related to Lunit SCOPE. Through this, the company aims to further enhance the technical completeness of Lunit SCOPE while laying the foundation to efficiently support pharmaceutical companies' new drug development processes.

At this conference, Lunit plans to present studies including ▲analysis of the impact of ErbB2 mutations on human epidermal growth factor receptor (HER)2 immunohistochemistry (IHC) expression across various cancer types ▲evaluation of the expression of the antigen CNTN4 expressed in cancer cells and its correlation with PD-L1 using AI across 18 cancer types ▲assessment of the correlation between CNTN4 expression and Keytruda responsiveness in gastric cancer.

Seobum Seok, CEO of Lunit, said, “We expect to demonstrate the further advanced technology of Lunit SCOPE and the progress of clinical research through it at this conference,” adding, “We will continue to verify that cutting-edge AI technology can play an important role in cancer treatment decisions.”

This content was produced with the assistance of AI translation services.